NASDAQ:CTRV - Nasdaq -
This Post Was Syndicated Under License Via QuoteMedia EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) — ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment ... Read
Midway through trading Friday, the Dow traded up 0.15% to 26793.43 while the NASDAQ fell 0.25% to 8,031.23. The S&P also fell, dropping 0.08% to 2,951.84. Leading and Lagging...
Following the market opening Friday, the Dow traded down 0.02% to 26,748.97 while the NASDAQ fell 0.24% to 8,031.65. The S&P also fell, dropping 0.16% to 2,949.50. Leading and...
SEAC – SEAC leads the way today as the best performing small cap stock, closing up 32.12%.
Gainers: Vislink Technologies (NASDAQ:VISL) +316%. Attis Industries (NASDAQ:ATIS) +32%. Valeritas Holdings (NASDAQ:VLRX) +27%. Harmonic (NASDAQ:HLIT) +26%. Akoustis Technologies (NASDAQ:AKTS) +21%. SM
HIVE – HIVE leads the way today as the best performing small cap stock, closing up 39.18%.
LGCY – LGCY leads the way today as the best performing small cap stock, closing up 80.00%.
Gainers: Axovant Gene Therapies (NASDAQ:AXGT) +40%. ContraVir Pharmaceuticals (NASDAQ:CTRV) +24%. India Globalization Capital (NYSEMKT:IGC) +17%. Pintec Technology (NASDAQ:PT) +14%. ObsEva SA (NASDAQ:
Gainers: Axovant Gene Therapies (NASDAQ:AXGT) +40%. ContraVir Pharmaceuticals (NASDAQ:CTRV) +24%. India Globalization Capital (NYSEMKT:IGC) +17%. Pintec Technology (NASDAQ:PT) +14%. ObsEva SA (NASDAQ:
Gainers: Axovant Gene Therapies (NASDAQ:AXGT) +33%. ContraVir Pharmaceuticals (NASDAQ:CTRV) +30%. ObsEva (NASDAQ:OBSV) +13%. Marker Therapeutics (NASDAQ:MRKR) +12%. Aptinyx (NASDAQ:APTX) +11%.Losers:
ContraVir Pharmaceuticals (NASDAQ:CTRV) +42% on FDA reaction to CRV431 plans.Axovant Gene Therapies (NASDAQ:AXGT) +21%.Seadrill (NYSE:SDRL) +11%.India Globalization Capital (NYSEMKT:IGC) +10%.Achieve
ARDS – ARDS leads the way today as the best performing small cap stock, closing up 47.34%.
ContraVir Pharmaceuticals (NASDAQ:CTRV) announces receiving positive FDA feedback to its pre-IND meeting for developing CRV431 in NASH.The FDA was positive on the existing preclinical data, supports t